{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:55Z","timestamp":1790913715417,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T00:00:00Z","timestamp":1341532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> To report our experience of the use of dasatinib in various phases of chronic myeloid leukemia (CML).<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> Ten patients in various phases of CML, not responding to imatinib and started on dasatinib, were included and analyzed. The baseline characteristics of the patients and their salient features including the duration and response to initial therapy as well as to dasatinib, were noted.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> Before starting dasatinib three patients were in chronic phase of CML while seven others were in the progressive phase (accelerated and blast phase) of CML. Half the patients developed transient grade 3 and 4 toxicities to dasatinib. Overall, the tolerability of the drug in all 10 patients was acceptable and none discontinued treatment. Three patients died due to progressive disease while the remaining seven are continuing the drug with the disease still under cytogenetic or hematological remission. Of the 10 patients, seven achieved complete hematological response and two of the accelerated phase\/blast crisis patients achieved complete cytogenetic response. Overall, dasatinib was able to control disease for a median of 20.6\u2003months.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> Despite small sample size and insufficient information on mutational analysis, dasatinib is effective in CML in INdia. Cost limits the use of second\u2010generation tyrosine kinase inhibitors in India. Our observation is not suitable for survival analysis but the difference made by dasatinib in progressive disease and its tolerability needs to be acknowledged.<\/jats:p>","DOI":"10.1111\/j.1743-7563.2012.01557.x","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T07:19:15Z","timestamp":1341559155000},"page":"375-379","source":"Crossref","is-referenced-by-count":3,"title":["Dasatinib in chronic myeloid leukemia: A limited Indian experience"],"prefix":"10.1111","volume":"8","author":[{"given":"Atul","family":"SHARMA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"BAHL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"RAINA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"KUMAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"GUPTA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,6]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200822010-00007"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70078-5"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/11535870-000000000-00000"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_5_9_2","unstructured":"European Medicines Agency.Sprycel dasatinib [online]. [updated 28 3 2012; cited 17 Aug 2011]. Available fromhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000709\/human_med_001062.jsp&mid=WC0b01ac058001d124&jsenabled=true."},{"key":"e_1_2_5_10_2","first-page":"899","article-title":"Chronic granulocytic leukemia. A study of 160 cases","volume":"38","author":"Kumar L","year":"1990","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860915)58:6<1357::AID-CNCR2820580629>3.0.CO;2-M"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.507416"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903479299"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/jco.2009.27.15_suppl.7007","article-title":"Dasatinib dose\u2010optimization study in chronic phase chronic myeloid leukemia (CML\u2010CP): three\u2010year follow\u2010up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression\u2010free survival (PFS) [abstract]","volume":"27","author":"Stone RM","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","unstructured":"SaglioG KantarjianHM HochhausAet\u2003al.Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML\u2010BP): 2\u2010year data from CA180\u2010035 [abstract]. Blood (ASH Annual Meeting Abstracts).2008 112. [cited 23 April 2012]. Available fromhttp:\/\/ash.confex.com\/ash\/2008\/webprogram\/Paper12009.html.","DOI":"10.1182\/blood.V112.11.3226.3226"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","unstructured":"Shah N BahceciE LambertA PloughmanL RadichJ.Resistance outcome and the development of mutations with dasatinib in patients with chronic\u2010phase chronic myeloid leukemia (CML\u2010CP) [abstract]. Blood (ASH Annual Meeting Abstracts).2009 114. Abstract 1122. 3226.[cited 23 April 2012]. Available fromhttp:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper22134.html.","DOI":"10.1182\/blood.V114.22.1122.1122"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1743-7563.2012.01557.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1743-7563.2012.01557.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:36:50Z","timestamp":1697441810000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1743-7563.2012.01557.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1743-7563.2012.01557.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-7563.2012.01557.x","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,6]]}}}